Evaluating Emetine for Viral Outbreaks (EVOLVE)

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

June 14, 2026

Study Completion Date

September 14, 2026

Conditions
COVID-19
Interventions
DRUG

Emetine Hydrochloride

To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.

DRUG

Placebo

Participant takes a placebo for 10 consecutive days.

Trial Locations (2)

21231

NOT_YET_RECRUITING

Johns Hopkins University, Division of Infectious Diseases, Baltimore

00000

RECRUITING

Bharatpur Hospital, Bharatpur

All Listed Sponsors
collaborator

Nepal Health Research Council

OTHER_GOV

collaborator

Bharatpur Hospital Chitwan

UNKNOWN

collaborator

Stony Brook University

OTHER

collaborator

Rutgers University

OTHER

lead

Johns Hopkins University

OTHER